FDA Panel to Evaluate Lykos’ Innovative Psychedelic Treatment for Post-Traumatic Stress Disorder

FDA, Lykos, psychedelic therapy, PTSD, mental health, clinical trials, review panel, innovative treatment, mental health breakthrough.

Novo Holdings Supports Reunion Neuroscience’s $103M Series A Funding for Pioneering Psychedelic Clinical Trials

Novo Holdings, Reunion Neuroscience, Series A funding, psychedelic clinical trials, mental health treatments, mental health innovation, venture capital, biotechnology, healthcare investments.

Reunion Neuroscience Secures $103 Million to Advance Psychedelic Therapies for Patients

Reunion Neuroscience, psychedelic therapies, mental health, fundraising, clinical trials, mental health treatments, alternative therapies, mental health innovation, patient care, biotech industry.